The clinical efficacy of the adipocyte-derived hormone leptin in metabolic dysfunction.
In this review, we would like to consider several aspects of the discovery of leptin and its evolution as a therapeutic agent. It has been shown that the administration of leptin in congenital leptin deficiency that there was improvement in satiety and weight loss. In hypoleptinemic patients with lipodystrophy, there is a dramatic improvement in glucose metabolism, dyslipidemia and hepatic steatosis. Leptin is the first and only adipokine administered to humans long term to produce such an effect.
Gorden
Phillip
P
Clinical Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. PhillipG@intra.niddk.nih.gov
Park
Jean Y
JY
D003920:Diabetes Mellitus / Q000188:drug therapy; D050171:Dyslipidemias / Q000378:metabolism; D005234:Fatty Liver / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007333:Insulin Resistance; D020738:Leptin / Q000172:deficiency / Q000627:therapeutic use*; D008060:Lipodystrophy / Q000188:drug therapy*; D009765:Obesity / Q000188:drug therapy*; D012527:Satiation / Q000187:drug effects; D015431:Weight Loss / Q000187:drug effects
D020738:Leptin; D005947:Glucose